Compare ALGM & IMVT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ALGM | IMVT |
|---|---|---|
| Founded | 1990 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Semiconductors | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.5B | 5.0B |
| IPO Year | 2007 | 2019 |
| Metric | ALGM | IMVT |
|---|---|---|
| Price | $37.25 | $27.35 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 11 | 9 |
| Target Price | ★ $44.27 | $30.78 |
| AVG Volume (30 Days) | ★ 1.7M | 1.2M |
| Earning Date | 05-07-2026 | 05-28-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.01 | N/A |
| Revenue | ★ $725,006,000.00 | N/A |
| Revenue This Year | $24.21 | N/A |
| Revenue Next Year | $17.93 | N/A |
| P/E Ratio | $3,830.10 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $16.39 | $13.36 |
| 52 Week High | $43.86 | $29.25 |
| Indicator | ALGM | IMVT |
|---|---|---|
| Relative Strength Index (RSI) | 60.29 | 60.97 |
| Support Level | $29.55 | $24.63 |
| Resistance Level | $38.15 | $27.71 |
| Average True Range (ATR) | 1.66 | 1.29 |
| MACD | 0.82 | 0.32 |
| Stochastic Oscillator | 85.50 | 89.86 |
Allegro Microsystems Inc is a designer, developer, fabless manufacturer, and marketer of sensor ICs and application-specific analog power ICs for automotive and industrial markets. Its Sensor IC allows customers to precisely measure motion, speed, position, and current, and Power ICs include high-temperature and high-voltage capable motor drivers, power management, and LED driver ICs. Its products are divided into three categories such as SENSE which includes Current Sensors, Switches and Latches, and Interface ICs among others; REGULATE which includes Regulators, ClearPower Modules, and LED Drivers; and DRIVE which includes BLDC Drivers, Brush DC, and others. Key revenue for the company is generated from Greater China and the rest from the United States, Japan, Europe, and other regions.
Immunovant Inc is a clinical-stage immunology company dedicated to enabling normal lives for people with autoimmune diseases. Its focus is on developing IMVT-1402, a potential inhibitor of the neonatal fragment crystallizable receptor (FcRn), to address autoimmune diseases driven by high levels of pathogenic immunoglobulin G (IgG) antibodies. FcRn is involved in preventing the degradation of IgG antibodies, and inhibition of FcRn has been shown to reduce levels of total IgG and pathogenic IgG antibodies. The company operates in a single operating segment, which includes all activities related to the research, development and manufacturing of its product candidates.